A new Inserm Transfert Technology Offers experience coming soon in April !

BIO12303-T1

Prophylactic HIV vaccine

The invention relates to mAb based chimeric proteins allowing direct in-vivo targeting of antigens to the dendritic cells. GMP manufacturing of a prophylactic vaccine against HIV is ongoing and first in man is expected to start end of 2018.


Keywords : Infectious diseases, vaccine, HIV, dendritic, DC, antigene targeting
Patent Application number : -
Patent Application date : -
Multidisciplinary field : -
Technology/Engineering : -
Technological Platform : -
Rare disease : -
Second indication : -
Inventors : Yves LEVY
Jacques BANCHEREAU
Publications : -

Related offers


The 10 Last viewed

You haven't seen any form yet.